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ABSTRACT
The aim of the current investigation is to develop a sustained-release dry powder inhalation
(DPI) formulation through continuous Hot Melt Extrusion (HME) process and see the impact of
Sodium Bicarbonate (SB) and Mannitol (MAN) on the hydrophobic Eudragit RL PO (ERLPO)
polymer. Ball milling and air-jet milling were utilized to have powder with a particle size range
that is required for inhalation. Air-jet milled formulations showed promising particle size results
compared to ball milled formulations. All solid-state characterization studies revealed no change
on Theophylline (TH) crystallinity or occurrence of drug-excipient interactions in physical
mixtures and formulations. X2 formulation released TH constantly over six hours and has an
acceptable particle size range for a DPI, therefore, it was chosen as the best formulation. Due to
the pores that created by SB during HME extrusion, X1 released about half of TH after 15 minutes
and reached the maximum release on the eighth hour, nevertheless, its particles size was not
appropriate for DPI. X3 had the most suitable particle size range for a DPI, however, it had no a
sustained-release behavior and its release was the same as a pure TH. For future studies, X2 will
be further investigated on Anderson Cascade impaction (ACI), a study that mimic the lung, and
in-vivo study will be considered based on the ACI result.
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1. INTRODUCTION
The local drug delivery approach has been concern of researchers over decades especially
the pulmonary drug delivery as a dry powder inhaler (DPI) [1]–[4]. Many researchers explored
this new route to treat many local diseases such as respiratory infection, Tuberculosis and Cystic
fibrosis, also administering Cyclosporine as an immune suppressive drug or Ibuprofen as a nonsteroidal anti-inflammatory agent [4]–[8]. High bioavailability, fast onset of action, bypass liver
metabolism, and absence of breath actuation and propellant have made DPI the most preferred
lung formulation [3], [9]. On the other hand, the lung has a limited volume and that would be a
problem for water-insoluble drugs, thus a water-soluble drug, Theophylline (TH), was chosen to
be the model drug on this investigation due to its moderate solubility in water, which is 7.36 mg
ml-1 [10].
Theophylline (Figure 1) is a bronchodilator and has efficiency for treating asthma and
chronic obstruction pulmonary disorder (COPD) [11]. Also, Barnes reported that at low doses in
asthma and COPD diseases, TH shows immunomodulatory actions and Fredholm also noticed that
theophylline improved corticosteroids anti-inflammatory property [12], [13]. However, TH has a
narrow therapeutic window and adverse reactions on gastrointestinal and cardiovascular systems,
therefore, preparing TH as an oral sustained-release tablet (as in the market right now) or a DPI
formulation would help to minimize these problems [14], [15]. Moreover, M. Malamatari et al.,
A. Alhalaweh et al., reported the crystallinity behavior of TH during the spray drying by different
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solid-state characterization (thermal and non-thermal) methods and stated that TH tends to
preserve its crystallinity even during the exposure to a high temperature [16], [17].
Hot-melt extrusion (HME) has gained a popularity among the pharmaceutical applications
over the past forty years due to the ability to produce several versatile formulations. HME’s ability
derived from its advantages over the traditional pharmaceutical processing techniques which are
including, but not limited to, continuous operation, solvent-free method, few processing steps, low
cost, and the possibility for industrial scale-up [18], [19].
A fine solid crystal suspension (FSCS) is a term has been used recently by L. Lin et al.
which combines two different techniques to produce a fine crystalline powder to be used as DPI
[20]. The first technique was using HME to produce a solid crystal suspension (SCS) which the
crystalline drug suspends in the crystalline excipient. This method showed a good physical stability
and low hygroscopicity [21], [22]. The other one was using the air-jet milling technique to produce
a fine particle size powder to be used for inhalation [20].
Mannitol (MAN) was chosen to play an important role in formulations and its
concentration will be dominant to produce SCS while formulations were extruded and to improve
the milling efficiency for having FSCS formulations. In addition, the good flow property of
mannitol would improve the aerosolization performance of formulations and increase the drug
release inside the lung after being mixed with the lung fluids due to its ability as a pore former
[23], [24].
Eudragit® RL PO (ERLPO) has been used commonly in HME process. Due to its
quaternary ammonium groups that act as salts, the permeability of this hydrophobic copolymer
toward dissolution media increased and that makes it a good candidate to be in the sustainedrelease formulations [25]–[28].
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The aims of this study were investigating the feasibility to produce FSCS formulations
using the HME and two dry milling techniques (a ball milling and an air-jet milling) to get a DPI,
studying the release profile of polymeric and non-polymeric FSCS formulations, and the
possibility of producing light and porous particles using Sodium Bicarbonate (SB) during the HME
process. Many reports used a polymer to produce a sustained-release powder for DPI by different
processing techniques, therefore, Eudragit® RL PO (ERLPO) was utilized in some formulations
by different concentrations to investigate if there is a release difference inside the limited lung
fluids.

Figure 1: Theophylline Structure
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2. MATERIALS AND METHODS
2.1. Materials
Anhydrous theophylline (TH) was purchased from Acros Organic (Thermo Fisher
Scientific, NJ, USA). Pearlitol® 160 C (Mannitol) MAN was obtained as a gift sample from
Roquette (1417 Exchange Street, P.O. Box 6647, Keokuk, IA 52632). Eudragit® RL PO
(ERLPO)was kindly gifted by Evonik industries (Piscataway, USA). Sodium bicarbonate (SB)
was purchased from Fisher Scientific (Hanover Park, IL, USA).

2.2. Methods
2.2.1. Hot Melt Extrusion
The active pharmaceutical ingredient at different drug loads was mixed with ERLPO, SB
and MAN (Table 1) using a V-shell blender (MaxiBlendTM, GlobePharma, North Brunswick, NJ,
USA) at 25 rpm for 15 min. The physical mixtures were extruded successfully using a co-rotating
twin-screw extruder (11 mm Process 11™, Thermo Fischer Scientific, Karlsruhe, Germany) with
standard screw design (Figure 2).
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Figure 2: HME standard screw design
2.2.2. Preparing the DPI formulation
DPI formulations were prepared using two dry milling techniques. The first one was ball
milling using (Mixer Mill MM400, Retsch GmbH & Co. Germany). 5 mg of each extruded
formulation was placed in a 25-ml stainless steel milling jar and accompanied by 3 stainless steel
balls (6 mm diameter each). The extrudates were milled for 30 min at 30-Hz oscillations. The
second technique was using air-jet milling (Model 00 Jet-O-MizerTM also known as Aljet mill,
Fluid Energy, Telford, PA, USA).

2.2.3. Differential Scanning Calorimetry (DSC)
The thermal behavior of TH, ERLPO, and other excipients was studied by DSC 25, TA
Instrument which was calibrated with indium. Samples (4–5 mg) were crimped in standard
aluminum pans and sealed with the standard aluminum lid. After that, they were heated and
scanned from 30 to 300℃ at a heating rate of 20℃ /min under a flow rate of 50ml/min of dry
nitrogen atmosphere. An empty aluminum pan was placed as a reference.
5

2.2.4. Power X-ray Diffraction (PXRD):
PXRD was performed using a Bruker D8 Advance (Bruker, Billerica, MA, USA) with a
Cu-source and theta-2theta diffractometer equipped with a Lynx-eye Position Sensitive Detector.
The generator was set to a voltage of 40 kV and a current of 30 mA. The samples were dispersed
on a low background Si sample holder and compacted gently with the back of a metal spatula. The
scan ran from 5° to 40° 2θ with a 0.05 step size at 3 s/step.

2.2.5. Fourier Transform Infrared Spectroscopy (FT-IR)
FTIR analysis was conducted in the spectral range of 4000–650cm-1 using Cary 660 and
Cary 620 FTIR Microscopes (Agilent Technologies, Santa Clara, CA, USA). The bench was
equipped with a MIRacle ATR (Pike Technologies, Fitchburg, WI, USA), that was fitted with a
single bounce, diamond-coated ZnSe internal reflection element. FT-IR was performed to
determine molecular interactions of pure TH and in the presence of SB, MAN and ERLPO in the
formulations before and after applying high shear forces and elevated temperatures.

Table 1: Formulations composition, HME process parameters, and drug content
Formulations

TH
%

X1
X2
X3

30
20
20

MAN ERLPO SB Temperature
%
%
%
°C
40
60
80

25
20
0

5
0
0

160
160
160
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Screw speed
(rpm)

Drug Content
(%)

150
200
200

99.8±0.4
100.6±0.1
100.2±0.2

2.2.6. Powder density and flow properties
The flowability of formulations was determined by measuring the bulk and tapped densities
to calculate Carr’s index (CI) and Hausner ratio (HR) (Table 2). The powder of each formulation
was placed into a 25-mL measuring cylinder and the bulk volume was recorded, then the cylinder
was tapped 100 taps manually and the new tapped volume was noted[14]. Based on preliminary
experiments, 100 taps were enough to reach the maximum powder reduction. Then Carr’s Index
and Hausner ratio were calculated using the following equations:
𝐶𝐼 = (

𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦−bulk density
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦

) × 100

𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑟𝑎𝑡𝑖𝑜 =

𝑡𝑎𝑝 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦

Table 2: Formulation densities, Carr’s index, Hausner ratio, and moisture content
Formulation
X1
X2
X3

Bulk Density
(g/cm3)
0.34±0.04
0.32±0.02
0.3±0.01

Tapped Density
(g/cm3)
0.46±0.03
0.41±0.03
0.36±0.02

CI
(%)
25
22.2
16.6

HR
1.33
1.28
1.2

Moisture content
(%)
2.49
0.7
0.68

2.2.7. Scanning Electron Microscopy (SEM)
The samples were placed on aluminum stubs held with a carbon adhesive film. Gold was
used to coat the samples by a Hummer 6.2 sputtering system (Anatech Ltd., Battlecreek, MI, USA)
in a high-vacuum evaporator. The surface morphology of every sample was analyzed by a scanning
electron microscope (SEM) operating at an accelerating voltage from 1.0 kV to 5.0 kV (JEOL
JSM-5600; JEOL, Inc., Peabody, MA, USA). FIJI/Image J software was used to record the pore
diameter and study the impact of SB on pore formation before and after the milling process.
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2.2.8. Moisture Content
Moisture content was studied by evaluating loss on drying (LOD) using a halogen moisture
analyzer balance (MB45 moisture analyzer, Ohaus, USA). The percentage of moisture was
estimated by drying 1-2 g of each formulation at 105 °C for 10 min (Table 2).

2.2.9. HPLC Analysis
Quantitative high-performance liquid chromatography (HPLC) was used as mentioned in
USP 38 with an isocratic mode of elution (Waters Corp., Milford, MA, USA) equipped with an
autosampler, UV/VIS detector and Empower software. The column was a reverse phase XTerra®
C18 (5µm, 150 mm x 4.6 mm) was used to analyze theophylline at 280 nm wavelength. The
mobile phase consisted of 92:7:1 % (v/v/v) of 0.01M sodium acetate trihydrate buffer: acetonitrile:
glacial acetic acid pumped at a flow rate of 1 mL/min and the injection volume was 10µL. The
samples were filtered using a 0.22µm filter (Millex® GV, Durapore® PVDF).

2.2.10. Drug Content
An amount, that has 50 mg of TH, of each extruded formulation was dissolved in 50 ml
water and TH concentrations were detected by HPLC system as mentioned previously on HPLC
analysis section. The correlation coefficient of the calibration curve was 0.999 over a concentration
range of 1-225 µg ml-1

2.2.11. Particle size distribution (PSD) by laser light diffraction
PSDs were determined using a Sympatec Helos equipped with a Cuvette module (SystemPartikel-Technik GmbH, Clausthal-Zel-lerfeld, Germany). Data were analyzed using the
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Sympatec WINDOX software. The particle size distribution of each air-jet milled formulation was
measured and particle diameters at the 10th (D10), 50th (D50), and 90th (D90) percentile were
observed and used to calculate the span by the following equation: Span=(d90-d10)/d50). A lower
span means a narrow size distribution (Table 3).

2.2.12. Drug release-study
Dissolution was performed for the extruded DPI formulations in phosphate-buffered saline
(1 mL, pH 7.4) in dialysis bag and then placed into the phosphate buffer dissolution medium
(37±0.5 °C, 100 rpm) using a dialysis bag with a molecular weight cut-off of 20,000 Da. To
accomplish the sink conditions and the saturation solubility of TH, 300 mL of dissolution media
was used and an exact amount was compensated during every sample withdrawn. The samples
were withdrawn at predetermined time intervals over eight hours. The samples were suitably
diluted and analyzed for theophylline content by UV spectrophotometry at 274nm wavelength[14].
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3. RESULTS AND DISCUSSION
3.1. Solid State Characterization
3.1.1. DSC
The thermal behavior of TH, MAN, ERLPO, and SB was analyzed by DSC. The pure TH
endothermic peak was observed at 275℃ (Figure 3). The DSC results revealed the crystalline
nature of TH in the extrudates and other excipients thermal stability during HME at the extrusion
temperature (160℃), but PXRD is required to proof the crystallinity of TH. Ball and air-jet milling
had no effect on the status of extruded formulations especially the crystallinity of MAN which was
seen and noticed after the HME. The TH melting peak showed a change in its thermal behavior in
the presence of MAN (Figure 4), it disappeared before and after the HME process, which is
probably explained by the hypothesis that it dissolved in the MAN during extrusion [16]. MAN’s
endothermic peak was sharp and seen at 170℃ in physical mixtures or extrudates.
Overlay

Figure 3: DSC thermal curves of pure TH, MAN, ERLPO, SB, and physical mixture
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Figure 4: DSC thermal curves of physical mixtures and extruded formulations

3.1.2. PXRD
PXRD studies of pure TH and formulation showed the presence of all characteristic peaks
of TH, thus, TH retained its crystalline nature after the exposure to a high temperature during the
HME process (Figure 5).

Figure 5: PXRD of pure TH and formulations
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3.1.3. FT-IR
TH showed prominent wavenumbers at 1704, 1659, and 1560 cm-1 [29]. At the first two
wavenumbers, FTIR revealed the presence of C=O stretching vibration of carbonyl groups and the
stretching vibration of imine group at 1566 cm-1 of TH (Figure 1) and other excipients peaks in
physical mixtures and all extruded formulations (Figure 6, Figure 7, and Figure 8) suggesting no
interaction occurred.
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Figure 6: FT-IR results of X1
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Figure 7: FT-IR results of X2
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Figure 8: FT-IR results of X3
3.2. Characterization of Morphology and Particle size
3.2.1. SEM
A cross-sectional area of the extrudates was examined by SEM to see the effect of HME
process and incorporation of Sodium Bicarbonate as a pore former. Figure 9 shows the image of
formulation X1 and the resulted pores. The pores were varied in size and shape which may be an
indication of places were SB distributed mostly inside formulations. On the preliminary study, it
was noticed that incorporation of MAN led to enhance the screw speed performance which resulted
in decreasing the residence time of formulations inside the HME and that led to decrease in the
number of pores. SB did not get the efficient time to transfer into Sodium Carbonate and release
all CO2. Furthermore, MAN helped to improve the torque situation during the process as its
concentration in formulations increases and that because of its good flow property.
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Figure 9: The SEM image of extrudate with Sodium Bicarbonate as a pore former

Figure 10: SEM images of ball milled formulations
The particle size and morphology of powder would have an influence on the dry powder
inhaler performance in the lung [30]. Alhalaweh et al. and M. Malamatari et al. pictured starting
materials of Theophylline and mannitol by SEM and they described their shapes as needle-shaped
particles and elongated particles, respectively [16], [17]. During the HME, materials liquefied, and
final product was strands. The milling micronized these strands into a powder which were shaped
differently than its origin as in Figure 10.
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Figure 10 showed the formulations after micronized by the ball milling. Particles size
differed from formulation to another and the range was approximately about 2-50µm. Also, it was
noticed that as mannitol amount increased in the formulation the particle size decreased. Therefore,
this change in size reduction supports the hypothesis that mannitol has a co-milling ability [31],
[32].

Table 3: PSD parameters
Formulation
X1
X2
X3

D10 (µm)
12.77
8.75
5.57

D50 (µm)
34.25
13.48
6.25

D90 (µm)
45.39
26.42
11.16

Span
0.9
1.3
0.8

3.2.2. PSD
The particle size distribution would be a key factor study on determining which is the
efficient milling method in our study. The D50 and D90 of each formulation give an impression and
a slight prediction about formulations’ behavior on the Anderson cascade impaction (ACI) study
which is considered a mimic for the lung system. The span of each formulation was a small number
and that illustrates the narrow particle size distribution which means most particles were around
the size of D50. X1 showed particles with bigger size than other formulations and that may be due
to the low percentage of MAN in it, but its result was considered a better than the ball milling
result when compare between them. X2 and X3 showed promising results especially when
focusing on the D50 which tells that the outcome percentages of half of the two formulations were
within or near the acceptable range of DPI. Furthermore, X3 might be the promising formulation
as a DPI due to its particles size which most of them were around the 6 µm.
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3.3. Moisture Content:
X1 formulation was observed to absorb moisture more than other formulations and that
related to sodium bicarbonate which has a hygroscopic nature [33], [34]. X2 has a water insoluble
polymer and mannitol, which is only in X3, that has no a moisture uptake even at high relative
humidity[35].

3.4. Drug release-study
The formulations (X1 and X2) were expected to have a sustained-release behavior due to
the presence of ERLPO, but the X3 was not (Table 1). X1 and X2 showed a variation on releasing
TH at the first time point and that might be related to the low ERLPO’s percentages that let TH
dispersed incompletely inside their matrix (Figure 11). Therefore, some TH dissolved in mannitol
and others dispersed on ERLPO. Furthermore, X1 exhibited a faster release on the first time point
than other formulation by releasing 50% of TH and that could be the effect of pores which were
generated by SB during the HME process. X2 showed the lowest release of TH content after 15
minutes among other formulations and reached its maximum release on the sixth hour. X3 and a
pure TH were expected to behave in the same way and they were almost the same.
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Figure 11: The release-study of all formulations
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